Cognitive performance is associated with glomerular filtration rate in patients with chronic kidney disease: results from the CKD-REIN cohort.
cognition
epidemiology
renal medicine
Journal
Journal of neurology, neurosurgery, and psychiatry
ISSN: 1468-330X
Titre abrégé: J Neurol Neurosurg Psychiatry
Pays: England
ID NLM: 2985191R
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
06
09
2022
accepted:
05
01
2023
medline:
17
5
2023
pubmed:
25
1
2023
entrez:
24
1
2023
Statut:
ppublish
Résumé
Chronic kidney disease (CKD) is associated with cognitive impairment in general population. We assessed the association between kidney and cognitive functions in patients with CKD and the influence of cardiovascular (CV) risk factors, and depression on this association. The CKD-Renal Epidemiology and Information Network cohort included 3033 patients with CKD stages 3-4, followed for 5 years. Cognitive function was assessed with the Mini-Mental State Examination (MMSE) and estimated glomerular filtration rate (eGFR) with the CKD-Epidemiology Collaboration equation-creatinin formula. Evolution of the MMSE score over time and its association with baseline eGFR were investigated with linear mixed models. We assessed the risk of incident cognitive outcome (hospitalisation or death with relevant International Classification of Disease-10 codes), with a Cox proportional hazard model. The mean age was 66.8, the mean eGFR was 33 mL/min/1.73 m In patients with CKD, lower eGFR was associated with worse cognitive performance and incident cognitive events, independently of demographics, CV risk factors and depression. NCT03381950.
Sections du résumé
BACKGROUND
Chronic kidney disease (CKD) is associated with cognitive impairment in general population. We assessed the association between kidney and cognitive functions in patients with CKD and the influence of cardiovascular (CV) risk factors, and depression on this association.
METHODS
The CKD-Renal Epidemiology and Information Network cohort included 3033 patients with CKD stages 3-4, followed for 5 years. Cognitive function was assessed with the Mini-Mental State Examination (MMSE) and estimated glomerular filtration rate (eGFR) with the CKD-Epidemiology Collaboration equation-creatinin formula. Evolution of the MMSE score over time and its association with baseline eGFR were investigated with linear mixed models. We assessed the risk of incident cognitive outcome (hospitalisation or death with relevant International Classification of Disease-10 codes), with a Cox proportional hazard model.
RESULTS
The mean age was 66.8, the mean eGFR was 33 mL/min/1.73 m
CONCLUSIONS
In patients with CKD, lower eGFR was associated with worse cognitive performance and incident cognitive events, independently of demographics, CV risk factors and depression.
TRIAL REGISTRATION NUMBER
NCT03381950.
Identifiants
pubmed: 36693722
pii: jnnp-2022-330347
doi: 10.1136/jnnp-2022-330347
doi:
Banques de données
ClinicalTrials.gov
['NCT03381950']
Types de publication
Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
457-466Investigateurs
Natalia Alencar de Pinho
(NA)
Carole Ayav
(C)
Christian Combe
(C)
Denis Fouque
(D)
Luc Frimat
(L)
Christian Jacquelinet
(C)
Maurice Laville
(M)
Sophie Liabeuf
(S)
Ziad A Massy
(ZA)
Christophe Pascal
(C)
Bruce M Robinson
(BM)
Roberto Pecoits-Filho
(R)
Bénédicte Stengel
(B)
Céline Lange
(C)
Marie Metzger
(M)
Elodie Speyer
(E)
T Hannedouche
(T)
B Moulin
(B)
A Klein
(A)
C Combe
(C)
J P Bourdenx
(JP)
A Keller
(A)
C Delclaux
(C)
B Vendrely
(B)
B Deroure
(B)
A Lacraz
(A)
T Lobbedez
(T)
I Landru
(I)
Z Massy
(Z)
P Lang
(P)
X Belenfant
(X)
E Thervet
(E)
P Urena
(P)
M Delahousse
(M)
C Vela
(C)
M Essig
(M)
D Clément
(D)
H Sekhri
(H)
M Smati
(M)
M Jamali
(M)
B Hacq
(B)
V Panescu
(V)
M Bellou
(M)
Luc Frimat
(L)
N Kamar
(N)
C Noël
(C)
F Glowacki
(F)
N Maisonneuve
(N)
R Azar
(R)
M Hoffmann
(M)
M Hourmant
(M)
A Testa
(A)
D Besnier
(D)
G Choukroun
(G)
G Lambrey
(G)
S Burtey
(S)
G Lebrun
(G)
E Magnant
(E)
M Laville
(M)
D Fouque
(D)
C Chazot
(C)
P Zaoui
(P)
F Kuentz
(F)
Informations de copyright
© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.
Déclaration de conflit d'intérêts
Competing interests: BS reports grants for the CKD-REIN cohort study from Amgen, AstraZeneca, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka, and Vifor France. ZAM reports grants for CKD-REIN and other research projects from Amgen, Baxter, Fresenius Medical Care, GlaxoSmithKline, Merck Sharp and Dohme-Chibret, Sanofi-Genzyme, Lilly, Otsuka and the French government, as well as fees and grants to charities from Astellas, Baxter, Daichii and Sanofi-Genzyme; these sources of funding are not necessarily related to the content of the present manuscript. DF reports grants for other research projects from Fresenius Kabi and Sanofi.The other authors declare that they have no competing interests.